Apollomics Inc. announced changes to its board of directors, with Mr. Po-Jen Hsueh resigning and Dr. Ya-Chi (Claudia) Huang appointed to fill the vacancy. Dr. Huang brings extensive experience in biotechnology investment and corporate governance to the Board. The Company’s Board now consists of seven members, including independent directors. Apollomics focuses on developing oncology therapies, with their lead program vebreltinib in a Phase 2 clinical trial for non-small cell lung cancer and other tumors with c-Met alterations. The Company cautions that forward-looking statements involve unknown risks and uncertainties.

Read more at GlobeNewswire: Apollomics Announces Changes to its Board of Directors and